Virtu Financial LLC Makes New $408,000 Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Virtu Financial LLC bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 27,715 shares of the company’s stock, valued at approximately $408,000.

Several other large investors have also modified their holdings of the stock. Premier Path Wealth Partners LLC bought a new stake in Amylyx Pharmaceuticals in the fourth quarter valued at about $298,000. Franklin Resources Inc. grew its position in shares of Amylyx Pharmaceuticals by 114.4% in the 4th quarter. Franklin Resources Inc. now owns 1,325,001 shares of the company’s stock worth $19,504,000 after acquiring an additional 707,134 shares in the last quarter. Sectoral Asset Management Inc. increased its holdings in shares of Amylyx Pharmaceuticals by 14.1% in the 4th quarter. Sectoral Asset Management Inc. now owns 84,055 shares of the company’s stock valued at $1,237,000 after acquiring an additional 10,400 shares during the last quarter. Graham Capital Management L.P. raised its position in shares of Amylyx Pharmaceuticals by 84.1% during the 3rd quarter. Graham Capital Management L.P. now owns 56,241 shares of the company’s stock valued at $1,030,000 after acquiring an additional 25,689 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Amylyx Pharmaceuticals by 5.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 387,620 shares of the company’s stock worth $5,706,000 after purchasing an additional 21,758 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Trading Down 1.8 %

AMLX opened at $1.62 on Wednesday. The business’s 50 day moving average is $1.85 and its 200-day moving average is $8.78. The stock has a market cap of $110.18 million, a PE ratio of -1.51 and a beta of -0.68. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $25.48.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its earnings results on Friday, May 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of $0.24 by ($0.70). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a positive return on equity of 4.14%. The business had revenue of $88.64 million during the quarter, compared to analyst estimates of $113.26 million. During the same quarter in the prior year, the business earned $0.02 earnings per share. As a group, analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.36 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on AMLX shares. The Goldman Sachs Group reissued a “neutral” rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th. Mizuho cut their target price on shares of Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday, May 14th. SVB Leerink lowered Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Amylyx Pharmaceuticals in a research report on Friday, May 10th. Finally, Robert W. Baird lowered Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research report on Monday, March 11th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $28.67.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.